# Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

> **NCT01702155** · PHASE1,PHASE2 · COMPLETED · sponsor: **Delta-Fly Pharma, Inc.** · enrollment: 69 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** DFP-10917

## Key facts

- **NCT ID:** NCT01702155
- **Lead sponsor:** Delta-Fly Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-10
- **Primary completion:** 2017-01-18
- **Final completion:** 2017-10-11
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702155, "Phase I/II Study of DFP-10917 in Patients With Acute Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01702155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*